Agile Therapeutics (NASDAQ:AGRX) Now Covered by

Equities researchers at assumed coverage on shares of Agile Therapeutics (NASDAQ:AGRXGet Free Report) in a report issued on Tuesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Separately, Maxim Group reaffirmed a “hold” rating on shares of Agile Therapeutics in a research report on Monday, March 18th.

Read Our Latest Stock Analysis on Agile Therapeutics

Agile Therapeutics Price Performance

Shares of NASDAQ:AGRX opened at $1.43 on Tuesday. The stock has a market cap of $9.81 million, a price-to-earnings ratio of -0.39 and a beta of 1.58. Agile Therapeutics has a 12-month low of $0.20 and a 12-month high of $3.30. The business’s 50 day moving average is $0.60 and its 200 day moving average is $0.86.

Agile Therapeutics (NASDAQ:AGRXGet Free Report) last announced its earnings results on Wednesday, May 15th. The specialty pharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter. The company had revenue of $5.72 million during the quarter.

Institutional Trading of Agile Therapeutics

A hedge fund recently raised its stake in Agile Therapeutics stock. Armistice Capital LLC increased its holdings in shares of Agile Therapeutics, Inc. (NASDAQ:AGRXFree Report) by 10.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 108,000 shares of the specialty pharmaceutical company’s stock after acquiring an additional 10,000 shares during the quarter. Armistice Capital LLC owned approximately 3.65% of Agile Therapeutics worth $211,000 as of its most recent SEC filing. 10.92% of the stock is owned by institutional investors and hedge funds.

About Agile Therapeutics

(Get Free Report)

Agile Therapeutics, Inc, a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

Read More

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with's FREE daily email newsletter.